ArticleMolecular therapy. Nucleic acids2017
In Vitro Selection of Cell-Internalizing DNA Aptamers in a Model System of Inflammatory Kidney Disease.
Article in Molecular therapy. Nucleic acids, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- CompELS vs SELEX: Comparative Aptamer Discovery Integrating Rational Libraries and Enzymatic Elution.ACS nano medicine · 2026Article
- RNA-based therapeutic opportunities for the treatment of kidney diseases.Nature reviews. Nephrology · 2026Review
- Aptamer-targeted anti-miR RNA construct based on 3WJ as a new approach for the treatment of chronic kidney disease in an experimental model.Gene therapy · 2025Article
- RNA-Based Therapies in Kidney Diseases.Journal of inflammation research · 2025Review
- Spotlight on Genetic Kidney Diseases: A Call for Drug Delivery and Nanomedicine Solutions.ACS nano · 2023Review
- Advances in Aptamer-Based Biosensors and Cell-Internalizing SELEX Technology for Diagnostic and Therapeutic Application.Biosensors · 2022Review
- Exosomal mitochondrial tRNAs and miRNAs as potential predictors of inflammation in renal proximal tubular epithelial cells.Molecular therapy. Nucleic acids · 2022Article
- Nucleic Acid Nanotechnology for Diagnostics and Therapeutics in Acute Kidney Injury.International journal of molecular sciences · 2022Review
- Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers.Frontiers in cell and developmental biology · 2022Review
- Uptake mechanisms of cell-internalizing nucleic acid aptamers for applications as pharmacological agents.RSC medicinal chemistry · 2021Review
- Oligonucleotide-Based Therapies for Renal Diseases.Biomedicines · 2021Review
- Aptamers: Uptake mechanisms and intracellular applications.Advanced drug delivery reviews · 2018Review
- Modular cell-internalizing aptamer nanostructure enables targeted delivery of large functional RNAs in cancer cell lines.Nature communications · 2018Article
- Aptamer Cell-Based Selection: Overview and Advances.Biomedicines · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is a progressive pathological condition marked by a gradual loss of kidney function. Treatment of CKD is most effective when diagnosed at an early stage and patients are still asymptomatic. However, current diagnostic biomarkers (e.g., serum creatinine and urine albumin) are insufficient for prediction of the pathogenesis of the disease. To address this need, we applied a cell-SELEX (systematic evolution of ligands by exponential enrichment) approach and identified a series of DNA aptamers, which exhibit high affinity and selectivity for cytokine-stimulated cells, resembling some aspects of a CKD phenotype. The cell-SELEX approach was driven toward the enrichment of aptamers that internalize via the endosomal pathway by isolating the endosomal fractions in each selection cycle. Indeed, we demonstrated co-localization of selected aptamers with lysosomal-associated membrane protein 1 (LAMP-1), a late endosomal and lysosomal marker protein, by fluorescence in situ hybridization. These findings are consistent with binding and subsequent internalization of the aptamers into cytokine-stimulated cells. Thus, our study sets the stage for applying selected DNA aptamers as theragnostic reagents for the development of targeted therapies to combat CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.